The Latest Biotechnology / Pharmaceuticals Articles from Streetwise Reports


Myovant Sciences Shares Rise on NDA Filing for Uterine Fibroid Combination Therapy Drug

  ()
Shares of Myovant Sciences traded 40% higher after the company reported that it has submitted a New Drug Application to the FDA for once-daily relugolix combination tablet for the treatment of women with uterine fibroids. read more >

Small-Cap Pharma Fast-Tracking Repurposed Drug for Covid-19

  ()
Algernon Pharmaceuticals is quickly moving ahead with a multinational Phase 2b/3 trial for Ifenprodil. read more >

Biotech's 'Multiple Sclerosis Therapy Shows Improvement in Disability'

Research Report
  ()
Atara Biotherapeutics' clinical trial design and results are reviewed in a ROTH Capital Partners report. read more >

Biotech Identifies Antibody with 100% SARS-CoV-2 Inhibition

Research Report
  ()
The goal of Sorrento Therapeutics to develop a Covid-19 antibody cocktail, including its progress, next steps and market opportunity, is reviewed in a Dawson James report. read more >

Mersana Therapeutics Trades 60% Higher on Positive Phase 1 Ovarian Cancer Trial Data

  ()
Shares of Mersana Therapeutics reached a new 52-week high price after the company reported positive interim data from the expanded portion of its Phase 1 study of XMT-1536 for treatment of ovarian cancer. read more >

Novavax Shares Rise 9% Upon Initiating Phase 1/2 COVID-19 Vaccine Clinical Trial

  ()
Novavax shares traded higher after the company reported it enrolled the first participants in its Phase 1 clinical study of NVX CoV2373. read more >

Vertically Integrated Hemp/CBD Player Sweet Earth Holdings Debuts on CSE

Contributed Opinion
  ()
With CBD showing some promise against Covid-19 and cannabis stocks rising, Peter Epstein of Epstein Research discusses the market with Sweet Earth Holdings executives. read more >

Surface Oncology Shares Trade Up 40% on Phase 1 Study Plans for SRF617 Combined with Merck's KEYTRUDA

  ()
Shares of Surface Oncology set a new 52-week high price after the company reported that it is partnering with Merck & Co. in an immuno-oncology study of SRF617, targeting CD39 in combination with KEYTRUDA® (pembrolizumab) in solid tumor patients. read more >

US Biopharma to Launch Phase 3 Trial in Bacterial Vaginosis

Research Report
  ()
Daré Bioscience's study, its prospects and the indication's U.S. market opportunity are discussed in a ROTH Capital Partners report. read more >

Arbutus Biopharma Trades 25% Higher on Phase 1 Hepatitis B Results

  ()
Shares of Arbutus Biopharma traded higher after the company reported significant and continuous reduction in HBsAg in 12 chronic hepatitis B subjects using 60 mg dosage of its AB-729 drug. read more >

Moderna Shares Rise 25% on Positive Phase 1 Coronavirus Vaccine Trial Data

  ()
Shares of Moderna Inc. traded higher, setting a new 52-week high price, after the firm reported positive interim results in its Phase 1 study of mRNA Vaccine (mRNA-1273) against SARS-CoV-2. read more >
News Update

Biopharma Seeks Ethics Approval in Australia to Test COVID-19 Treatment

News Update
  ()
Algernon Pharmaceuticals intends to test a repurposed drug for this indication, in a trial in three countries. read more >

Allogene Therapeutics Shares Climb 30% on Phase 1 Relapsed/Refractory NHL Study Data

  ()
Shares of Allogene Therapeutics traded higher and reached a new 52-week high price after the company reported initial results from its Phase 1 relapsed/refractory non-Hodgkin lymphoma trial. read more >
News Update

Biotech Expands Antibody Research Across Multiple Neurodegenerative Diseases and Covid-19

News Update
  ()
ProMIS Neurosciences advances its various antibody programs related to neurodegenerative diseases and viral infections such as Covid-19. read more >
News Update

Acceleration of COVID-19 Vaccine Programs Could Benefit U.S. Biotech

Research Report
  ()
The development timeline for Inovio Pharmaceuticals' coronavirus vaccine candidate is discussed in an H.C. Wainwright & Co. report. read more >

MyoKardia Shares Get a Jolt from Positive Phase 3 HCM Clinical Trial Results

  ()
Shares of MyoKardia traded 60% higher, setting a new 52-week high price, after the company reported that it met all primary and secondary endpoints in the Phase 3 EXPLORER study of mavacamten in treatment of obstructive hypertrophic cardiomyopathy. read more >
News Update

Pharmaceutical Firm Gains Ethics Approval for Phase 2 Human IPF and Chronic Cough Trial

News Update
  ()
Algernon Pharmaceuticals received ethics approval in Australia for a Phase 2 human clinical study of NP-120 (Ifenprodil) for use in treatment of idiopathic pulmonary fibrosis and chronic cough. read more >

Protagonist's Shares Nearly Double After Reporting Q1 Earnings and Positive Phase 2 Trial Results

  ()
Shares of Protagonist Therapeutics traded higher and reached a new 52-week high price after the company released Q1/20 financial results and positive data from its Phase 2 study of PTG-300 in patients with polycythemia vera, a type of blood cancer. read more >

California Biotech Partners for Manufacture of COVID-19 Vaccine Candidate

Research Report
  ()
Arcturus Therapeutics Holdings' arrangement is explained and commented on in an H.C. Wainwright & Co. report. read more >
News Update

Biotech Develops Antagonists for Protein Tied to Neurodegenerative Diseases

News Update
  ()
ProMIS Neurosciences' antagonists prevent dysfunctional protein aggregation. read more >

Horizon Therapeutics Shares Rise 15% on Strong Q1 Results and Raised F/Y Sales Guidance

  ()
Shares of Horizon Therapeutics traded higher setting a new 52-week high price after the company reported a 27% y-o-y increase in net sales for Q1/20 and raised FY/20 net sales guidance. read more >

Building a Better Covid-19 Antibody Test

  ()
ProMIS is harnessing its unique technology platform to develop a more error-free antibody test. read more >

Alexion's Buyout of Portola Pharmaceuticals Gets Investors' Blood Flowing

  ()
Shares of Portola Pharmaceuticals traded 130% higher after the company reported that it has received an $18 per share buyout offer from Alexion Pharmaceuticals. read more >
News Update

Firm Creates Novel Intrabodies for ALS and Other Neurodegenerative Diseases

News Update
  ()
ProMIS Neurosciences reported it has generated novel intrabodies that are highly selective for misfolded forms of TAR DNA-binding protein 43 implicated in several neurologic disorders. read more >

Stemline Shares Take Off on $677 Million Buyout Offer by Global Pharmaceutical Firm

  ()
Shares of Stemline Therapeutics traded 150% higher after the company reported that it has entered into a definitive agreement to be acquired by Italy's Menarini Group in a deal valued at up to $677 million. read more >
Showing Results: 1 to 25 of 116 Next

Get Our Streetwise Reports Newsletter Free and be the first to know!

A valid email address is required to subscribe